2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2654

Comparison of Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2649

Comparison of Biopsy Proven Giant Cell Arteritis in North America and South Europe: A Population-Based Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2494

Comparison of Comorbidity in Spondyloarthritis: Influence on Inflammatory Activity in Patients with Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2366

Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Switch to Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2067

Comparison of Medication New User Definitions in Multi-Specialty EMR Data

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Abstract Number: 2639

Comparison of Patient Self-reported Data to Physician-driven Cohorts in Patients with Eosinophilic Granulomatosis with Polyangiitis

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2099

Comparison of Single and Dual Latent Tuberculosis Screening Strategies Before the Initiation of Biologic and Targeted Therapy in Rheumatological Patients in Hong Kong

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2107

Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2688

Comparisons of Strategies for Diagnostic Assessment in Giant Cell Arteritis: Results from an International Observational Cohort

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2132

Complement Component 3 as Biomarker of Cardiometabolic Risk in Rheumatic Diseases: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Systemic Lupus Erythematosus

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2146

Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 1931

Comprehensive Characterization of the Immune Infiltrate of Skin Biopsies from Cutaneous Lupus Erythematosus Patients Using Single Cell RNAseq

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2590

Computer Vision Applied to Dual Energy Computed Tomography Images for Precise Calcinosis Cutis Quantification in Patients with Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2386

Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2191

Construct Validity of OMERACT Ultrasound Knee Scores with Pain, Other Symptoms, Radiographic and MRI Findings

Osteoarthritis – Clinical Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].